LIAISON XS, the new platform targeting small size laboratories launched in Europe in 2019, currently also available in the U.S. market.
Acquisition of a product portfolio based on the ELISA immunodiagnostic technology from Siemens and access to Siemens' ELISA clients.
Commercialization in China of DiaSorin Hepatitis B, C and HIV tests on DiaSorin LIAISON XL LAS connected to Beckman Coulter’s leading automation solutions, the Power Express and Power Processor automated sample processing systems.
Agreement to provide a fully-automated solution (CLIA) for Hepatitis A, B, C and HIV tests in the U.S. on the LIAISON platforms. DiaSorin and Beckman Coulter are working together to get the approval from the Food and Drug Administration (FDA) to market these CLIA test in the U.S. territory.
Co-development of the new CLIA release of QuantiFERON®-TB Gold Plus diagnostic test available on the LIAISON family platforms.